A computer program called DrugPredict has been developed to repurpose FDA-approved drugs for new indications, including the potential treatment of epithelial ovarian cancer. The researchers found that common pain medications like aspirin can kill ovarian cancer cells, and NSAIDs may also have applications in this area.
A new blood test has been developed to detect ovarian cancer with high accuracy, using microRNA profiling to distinguish between cancerous and benign tumors. The test shows promise in accurately predicting ovarian cancer, even when other methods fail.
Researchers discovered that tumor cells in the fallopian tubes of women at high-risk for ovarian cancer can be detected years before they develop into the disease, providing a potential window of time for early detection and intervention. The study identified TP53 gene mutations as an early indicator of ovarian cancer development.
A study of nine women suggests that ovarian tumors may originate in the fallopian tubes, providing insights into cancer origin and potential prevention strategies. The researchers found identical genetic errors in chromosome 17 and BRCA genes in all patients, supporting the fallopian tube theory.
A new study suggests that many pelvic tumors in women may have a common origin in the fallopian tubes, which could lead to new strategies for preventing and early detecting ovarian cancer. The research found that ovarian cancer cells share genetic similarities with cells covering the tips of fallopian tubes.
A recent study led by Mayo Clinic researchers found that tumor-infiltrating lymphocytes present in high-grade ovarian cancer tumors can predict patient survival. The study analyzed over 5,500 patients from nine countries and discovered that higher levels of these immune cells were associated with better outcomes.
A study published in JAMA found that biomarkers indicating diminished ovarian reserve were not associated with reduced fertility in women aged 30-44 attempting natural conception. Low AMH or high FSH levels were not linked to lower fecundability or cumulative probability of conceiving.
A new NIH-funded study finds that biomarkers for ovarian reserve do not predict fertility in older women attempting to conceive. Hormone levels linked to menopause onset were also found to have no association with conception rates.
Researchers at Notre Dame's Harper Cancer Research Institute have made a breakthrough in understanding how ovarian cancer cells spread throughout the body. They found that a specific membrane proteinase called MT1-MMP plays a crucial role in regulating the transition of cancer cells from floating to sticking phases.
The ARIEL3 trial shows rucaparib maintenance therapy significantly improves progression-free survival in patients with high-grade ovarian cancer and BRCA mutations. The medication also benefits patients with homologous recombination deficient tumors, increasing overall response rates.
The ICON8 trial confirms standard dosing of paclitaxel is safe and effective for European patients with ovarian cancer. The study found no benefit to dose-dense regimens in terms of progression-free survival, but noted a slight increase in grade 3-4 toxicity.
Researchers at The Wistar Institute have discovered a potential new therapeutic strategy for ovarian clear cell carcinoma, a difficult-to-treat form of ovarian cancer. By targeting the activity of histone deacetylase 6, a protein that suppresses tumor suppressive functions, they were able to increase apoptosis in tumor cells and reduce...
A new study suggests that ovarian tissue freezing is a superior option to egg freezing for preserving fertility, reversing menopause, and promoting natural conception. Nearly 37% of women who underwent the procedure were able to have children later in life, with nearly two-thirds experiencing restored natural fertility.
A new study from Duke University Medical Center questions the effectiveness of risk-reducing mastectomy for women with BRCA mutations who have already had ovarian cancer. The procedure is found to be cost-effective only for women diagnosed between 40-50 years old and at least five years post-ovarian cancer diagnosis.
A study by St. Jude Children's Research Hospital found that abdominal radiation increases the risk of premature ovarian insufficiency in female cancer survivors, which can lead to infertility and poor overall health. Researchers recommend estrogen replacement therapy to mitigate these risks.
A study has shown that an inexpensive fertility drug can be just as effective as more recent reproductive hormones in treating unexplained infertility. The 50-year-old drug, taken orally, was found to have a comparable pregnancy rate to newer hormones used in intrauterine insemination (IUI) with ovarian stimulation.
A new CT Perfusion technology has been developed to measure blood flow and predict how well ovarian cancer patients will respond to treatment. The study found that a decrease in blood flow is associated with longer survival times, while an increase is linked to shorter survival times.
A team of researchers at Fred Hutchinson Cancer Center will use recent technological advances in proteogenomics to identify biomarkers predicting treatment response and novel therapeutic targets for ovarian cancer. The goal is to improve understanding of drug resistance and ultimately enhance patient outcomes.
A study published in Oncogene has shed new light on the molecular mechanisms of ovarian cancer spread. Researchers found that N-cadherin plays a key role in metastasis by enabling cancer cells to anchor to new sites in the body, and that disrupting this process may provide a therapeutic strategy.
A study of nearly 10,000 women with BRCA1 and BRCA2 mutations found age-specific breast and ovarian cancer risks that vary by mutation location and family history. The findings indicate a need for individualized counseling incorporating both family history profiles and mutation location to inform preventive strategies.
Researchers have identified a new combination therapy that may improve survival for women with ovarian cancer by eradicating chemotherapy-resistant tumors. The treatment, involving carboplatin and birinapant, showed promise in mice and human tumor models, with 50% of samples responding to the therapy.
Researchers have developed a new test that can detect ovarian cancer months earlier than current methods, potentially improving five-year survival rates. The test uses synthetic biomarkers that interact with tumor proteins to release fragments in urine samples.
Scientists are working on tweaking T-cell therapy for leukemia to apply to solid tumors like ovarian cancer. The researchers identified proteins overproduced by ovarian cancer cells and found that engineered T cells can kill both human and mouse ovarian cancer cells in the lab.
Researchers have developed a new imaging test that can measure Poly (ADP-ribose) Polymerase 1 (PARP-1) levels in ovarian cancer patients, helping doctors identify those most likely to benefit from emerging PARP inhibitor therapy. The study used a novel radiotracer technology and PET scans to confirm findings in patients.
A combination of a PARP inhibitor and a kinase inhibitor showed significant tumor shrinkage in 36% of patients with platinum-resistant ovarian cancer, a surprising improvement over solo PARP inhibitor treatment. The treatment was well-tolerated, with four patients discontinuing due to toxicity.
Researchers from Fred Hutchinson Cancer Center are presenting new developments in immunotherapy and proteomics at the American Association for Cancer Research Annual Meeting. A new adoptive T-cell therapy for ovarian cancer has shown promising results, while a vaccine adjuvant has boosted immune responses to sarcomas.
A genome-wide analysis identified 30 known risk variants, accounting for 6.5% of the inherited component of risk. The variants are common and have small effects on risk, with women carrying multiple variants still having a low lifetime risk of 2.8%.
Researchers discovered that male hormones, specifically androgens, play a crucial role in the development of female chicken ovaries. The study found disruptions in ovarian structure when androgen receptors were suppressed, potentially affecting egg-laying rates.
Researchers have identified a protein biomarker, CD151, expressed on tumour cells of high-grade serous ovarian cancer, which is linked to poor prognosis. The study provides new information about possible targets for ovarian cancer treatment and has the potential to develop a clinical screening tool.
Research at the University of Illinois Chicago found that blocking a protein on ovarian cancer cells can prevent its spread to other organs. The study's lead researcher believes this discovery could be a key to developing new treatments for the disease.
TGen researchers will test triptolide as a potential drug targeting SCCOHT, an aggressive form of ovarian cancer that affects mostly girls and young women. The grant aims to improve the understanding of ovarian cancer biology and potentially develop new treatments for this devastating disease.
A personalized strategy involving frequent CA125 blood tests and ultrasound examinations could improve the chance of detecting tumors at early stages. This approach reduced the risk of diagnosis with advanced cancer in high-risk women who chose to delay recommended preventive surgery.
Researchers will utilize a unique odor signature to create a portable screening device for early-stage ovarian cancer diagnosis. The project aims to improve survival rates by identifying the disease at its initial stages.
A new study has found that defects in the EMSY gene, similar to BRCA genes, spur cancer growth independently of BRCA1 and BRCA2 protection. The research suggests new treatment options for women with normal BRCA genes who develop breast and ovarian cancer.
Researchers developed a blood test to predict ovarian cancer patients' response to chemotherapy using tumour DNA levels. The test identified patients whose tumour DNA count dropped by more than half after one cycle of chemotherapy as those likely to respond well to treatment.
Researchers identified a molecule called AXL which triggers the spread of an aggressive form of ovarian cancer. Blocking AXL may be an effective treatment option for patients with Mes subtype ovarian cancer.
Researchers at The Wistar Institute have developed a combination therapy that improves chemoresistance in ovarian cancer. BET inhibitors can suppress ALDH activity, making treatment more effective when used with cisplatin. This approach has shown extended survival rates and delayed tumor growth in mice.
Researchers at Boston University School of Medicine have discovered a potential treatment option for ovarian cancer by combining calpeptin with epigenetic inhibitors. The therapy shows promise in killing cancer cells and preventing their growth, offering new hope for women affected by the disease.
Research from Kumamoto University has discovered that a natural compound isolated from onions, onionin A, exhibits anti-ovarian cancer properties. ONA inhibits the growth of ovarian cancer cells and enhances the effects of anti-cancer drugs, making it a promising treatment option.
PharmaMar announces completion of Phase 3 pivotal study CORAIL with lurbinectedin (PM1183) for platinum-resistant ovarian cancer. The study demonstrates potential therapeutic alternative for patients who relapse after standard treatment. PharmaMar has successfully recruited 443 patients from over 100 hospitals in Europe and the USA.
Tumor cells attract macrophages by releasing cytokines, which secrete growth factors that help tumor cells form spheroids and grow. Inhibiting these growth factors reduces tumor cell proliferation in a mouse model of ovarian cancer. This study sheds light on the early stages of ovarian tumor metastasis.
Researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas, pointing to possible new treatments. The study identified key mutations in cancer genes that may explain the mixed tissue characteristics of these tumors.
The ENGOT-OV16/NOVA trial shows niraparib significantly improves progression-free survival in recurrent ovarian cancer patients, with median survival rates up to 21 months. Niraparib also improves secondary endpoints, including time to first subsequent treatment and chemotherapy-free interval.
Researchers found that increased cell membrane fluidity enhances auranofin's ability to induce DNA damage and cellular oxidation in ovarian cancer cells. This could lead to improved treatment outcomes by increasing the drug's effectiveness against cancer cells with fluid membranes.
Global trends show a decline in ovarian cancer deaths in the EU and USA between 2002 and 2012, with declines also seen in Australia and New Zealand. The main reason is the use of oral contraceptives, which provide long-term protection against ovarian cancer.
Researchers have discovered that female ocellated wrasses prefer sperm from nesting males over sneaker males, even when fertilization occurs externally. This phenomenon, known as cryptic female choice, is driven by the ovarian fluid released during spawning, which enhances sperm velocity and attraction to the egg.
The Independent Data Monitoring Committee approved PharmaMar's CORAIL study of PM1183 in patients with platinum-resistant ovarian cancer. The pivotal Phase III trial evaluates the efficacy of PM1183 compared to standard treatments.
A new Northwestern Medicine study finds that ovarian environment changes with age, leading to decreased egg quality and fertility issues. Fibrotic and inflamed ovaries are identified as key factors contributing to this decline.
A recent study by the Medical University of South Carolina found that African American women with lower socioeconomic status are at a higher risk of developing ovarian cancer. The study revealed a significant inverse association between SES and ovarian cancer risk, with women having a college degree or higher experiencing a 29% lower r...
Rice University bioengineer Junghae Suh has been awarded a prestigious R01 grant to research the use of viral gene therapy to fight ovarian cancer. The grant will help Suh and her lab adapt viruses to recognize extracellular enzymes overexpressed by ovarian-cancer tumors and deliver therapeutic genes to diseased cells.
Researchers have found a way to detect ovarian cancer early using a protein test, providing new hope for patients. An enzyme called SIK2 has been identified as key in making ovarian cancer more deadly, offering a potential new treatment target.
Researchers at The Wistar Institute have identified a specific receptor-protein expressed on the surface of ovarian tumor cells, offering a highly targeted therapeutic target for immunotherapy. This technology uses chimeric endocrine receptor-expressing T-cells to selectively eliminate cancerous cells with minimal adverse effects.
Researchers have identified BRCA1 mutations that predict treatment resistance in breast and ovarian cancers. Studies found that tumors with these mutations express a RING-deficient BRCA1 protein, leading to poor treatment responses.
Researchers at Mayo Clinic developed a new method to detect ovarian cancer recurrence using liquid biopsies from blood tests and DNA sequencing. This approach allows for earlier intervention and more effective individualized treatment by monitoring genetic changes in circulating cell-free DNA.
A new streamlined approach to genetic testing for women with ovarian cancer allows for faster and more affordable testing, enabling personalized cancer management and cancer prevention strategies. The test has been widely adopted in the UK and internationally, with estimates suggesting it could save £2.6M per year.
A new study shows that removing fallopian tubes during hysterectomies can help prevent ovarian cancer without compromising surgical outcomes. The procedure has been widely adopted in Kaiser Permanente's Northern California system, with no increase in complications or length of stay.
Researchers at Cold Spring Harbor Laboratory have identified a new pathway in ovarian cancer cells that can be targeted by drugs, reducing metastasis. The newly uncovered pathway depends on activity of protein FER, which activates receptor MET, leading to elevated motility and invasiveness.
A new study published in ecancermedicalscience found that online information about ovarian cancer can cause as much worry as comfort for women at high risk. The researchers suggest that patients should seek guidance from healthcare professionals and credible websites to make informed decisions.
A recent study has identified over 200 proteins involved in cell movement and immune system function that are implicated in ovarian cancer progression. By analyzing the proteomes of 169 ovarian cancer patients, researchers have gained new insights into the biology of the disease and potential targets for treatment.
Researchers found a strong five-gene signature in all patients who succumbed to the disease, regardless of their length of survival. The team also tested HXR9, which blocked HOX gene function, forcing cancer cells to close down and die, and found that combining it with cisplatin significantly increased cancer cell killing.